Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections
NCT ID: NCT02801383
Last Updated: 2016-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
100 participants
INTERVENTIONAL
2015-09-30
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
NCT01824992
Yallaferon in Chinese Population
NCT02593968
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
NCT00002327
Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance
NCT04781023
Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants
NCT02382419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment
Yallaferon®， the recombinant human interferon α-2b gel
controlled group
received 1g gel (without biological active ingredient) every other day for consecutive 6-10 courses of treatment
gel without active ingredient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yallaferon®， the recombinant human interferon α-2b gel
gel without active ingredient
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HPV DNA typing test for HPV-16 and/ or HPV-18 positive in 1 month.
Exclusion Criteria
* Associated with fungal vaginitis, trichomonas vaginitis, HIV positive patients;
* Associated with acute, severe bacterial or viral infection;
* Autoimmune diseases;
* Within 3 months before screening patients used corticosteroids, immunosuppressants or other antiviral drugs;
* Allergies or allergy to the drug known ingredients;
* History of suffering CNS diseases, epilepsy and/or psychological disorder;
* Pregnant and lactating women;
* The researchers do not consider it appropriate clinical trials.
25 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lee's Pharmaceutical Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Jian Zhao
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jian Zhao, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Zhaoke-201509-RHI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.